BridgeMD
Tests treatment safety and results for Toxic Epidermal Necrolysis
Official title Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis
ClinicalTrials.gov ID: NCT06119490
What this study is testing
What is Abrocitinib?
Abrocitinib is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for toxic epidermal necrolysis.
Also referred to as Solu-Medrol®.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- To evaluate the efficacy and safety of methylprednisolone combined with the JAK inhibitor abxitinib and tofacitinib in the treatment of toxic epidermal necrolysis
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 70
You may be able to join if
- Age 18 and above.
- Diagnosed with SJS/TEN according to the Registry of Severe Cutaneous Adverse Reactions (RegiSCAR) criteria.
- Liver and kidney function is within acceptable ranges.
- Blood parameters, including complete blood count, coagulation function, and platelet count, are within acceptable ranges.
- Patients must sign an informed consent form, understanding the risks and potential benefits of the treatment.
You likely can't join if
- History of allergy to JAK inhibitors.
- Pregnant or breastfeeding women.
- Severe infectious conditions.
- History of central nervous system demyelinating diseases.
- History of lymphoproliferative diseases.
- Active and latent tuberculosis.
See the full eligibility criteria
- Age 18 and above.
- Diagnosed with SJS/TEN according to the Registry of Severe Cutaneous Adverse Reactions (RegiSCAR) criteria.
- Liver and kidney function is within acceptable ranges.
- Blood parameters, including complete blood count, coagulation function, and platelet count, are within acceptable ranges.
- Patients must sign an informed consent form, understanding the risks and potential benefits of the treatment.
- Patients need to be capable of participating in follow-up visits and treatment plans.
- History of allergy to JAK inhibitors.
- Pregnant or breastfeeding women.
- Severe infectious conditions.
- History of central nervous system demyelinating diseases.
- History of lymphoproliferative diseases.
- Active and latent tuberculosis.
- HIV carriers with a CD4+ T cell count lower than (\<200/mL).
- Active HBV/HCV infection.
- Coagulation disorders or a tendency for thrombosis.
- Significant abnormalities in blood routine indicators.
- Liver or kidney dysfunction.
The study team makes the final eligibility decision.
Where it's taking place
- Fuzhou, Fujian, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 70 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Fuzhou, Fujian, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.